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Lung cancer arises from epithelial cells that line the air passages of the lungs.  It is 
the second most common malignancy in the United States; trends suggest that over 
228,000 new patients will be diagnosed with lung cancer in 2013.  Due to the fact that lung 
cancer is highly aggressive, it has proven difficult to control.  The 5-year survival rate has 
been shown to be only 15.9%, despite the advances made in terms of diagnosis and 
treatment.  Therefore, we are faced with the problem of finding more effective methods 
that allow for an earlier diagnosis and the improved treatment of lung cancer.  This study 
attempts to address these issues by investigating Tarsh, a novel molecule that is involved in 
the regulation of cellular senescence.  Previous studies have shown that Tarsh is expressed 
in normal lung cells, but is significantly downregulated in lung tumors.  These studies also 
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determined that Tarsh is likely dependent upon the expression of p53, a tumor suppressor 
gene.  The current study investigated these results, in addition to the biological effects of 
ectopically increasing Tarsh and/or knocking down p53 expression in two lung cancer cell 
lines: A549 and H1299 cell lines.  It was determined that increasing the expression of 
Tarsh decreased the rate of proliferation in both cell lines.  Additionally, it was shown that 
the knockdown of p53 increased proliferation in A549 cells.  In regards to the migration 
rate of these cell lines, the overexpression of Tarsh decreased migration in A549 cells, but 
had no effect on H1299 cells.  However, the role of p53 in migration is still unclear.  The 
results of this study suggest that the knockdown of p53 decreases cell migration in A549 
cells.  This contradicts the fact that H1299 cells do not express p53, yet was found to have 
the highest migration rate.  It is evident that a further investigation is needed to make more 
concrete conclusions.  Nevertheless, the suppressive features of Tarsh on cell proliferation, 
and possibly migration, make it a promising target of research for lung cancer therapy. 
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Introduction 
 
 
1.1: Cancer 
Each year, cancer causes about 570,000 deaths, equating to about 25% of the 
annual mortalities, in the United States(7).  In addition, cancer affects people on a global 
scale, claiming numerous lives due to its high adaptability.  In essence, it is an ailment 
involving the uncontrolled growth of cells in the body.  Failure rates with treatment, and 
high mortality rates associated with cancer, can be contributed to the ability of these cells 
to metastasize.  This results in the spreading of the cells to adjacent tissues, and eventually 
distant organs(3). 
Cancer types may be grouped into five categories, which include carcinomas, 
sarcomas, leukemias, lymphomas, and cancers of the central nervous system (CNS).  
Carcinomas are cancers that arise from the skin, or in tissues that border internal organs.  
Carcinomas can be further divided into subtypes, based on their histology.  These 
subdivisions include adenocarcinomas, basal cell carcinomas, squamous cell carcinomas, 
and transitional cell carcinomas.  Sarcomas are cancers that originate in connective or 
supportive tissue, such as cartilage, bone, muscle, fat, and blood vessels.  Leukemias 
develop from blood-forming tissues, and produce an excess of abnormal white blood cells.  
These abnormal cells eventually replace pre-existing, normal white blood cells.  
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Lymphomas are cancers that involve the lymphatic system, a subdivision of the immune 
system.  These cancers may be categorized as either Hodgkin type lymphomas, which 
develop from abnormal B-cells, or non-Hodgkin type lymphomas, which develop from 
abnormal B-cells or T-cells.  Finally, CNS cancers start in the tissues of the brain and 
spinal cord, and arise mainly from astrocytes, the cerebellum, or the spinal cord(18). 
Regardless of origin, however, all cancers are believed to be the product of genetic 
mutations in normal cells.  These newly transformed cells result in a tumor phenotype, and 
they often gain the ability to proliferate, survive, and invade surrounding tissues without 
limit.  Under normal circumstances, these physiological processes are highly regulated.  
However, in the case of tumor phenotypes, the deregulation of these processes leads to 
cancer metastasis.  The downregulation of these inhibitory effects may be linked to 
mutations in tumor-suppressor genes.  Normally, these genes function to limit cell growth, 
but their inactivation during cancer leads to uncontrolled proliferation.  The activation of 
another set of genes, known as proto-oncogenes, may also result in a cancer phenotype.  
These genes function to enhance cell growth, and in cancer, their levels are overexpressed.  
It is likely that mutations in both tumor-suppressor and proto-oncogenes act 
synergistically.  Therefore, a combination of mutations in both of these genes may cause 
abnormal protein expression and characteristics that lead to tumor phenotypes(11). 
Environmental factors that contribute to the genetic mutations associated with 
cancer include smoking, alcohol, and ultraviolet (UV) radiation exposure.  Routinely 
consuming alcohol significantly increases the risk of developing cancer.  Previous studies 
have shown a positive correlation between alcohol consumption and cancer development, 
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particularly in upper aerodigestive tract carcinomas.  Specifically, ethanol has been found 
to be the main culprit responsible for cancer formation.  Ethanol can aid in the absorption 
of other carcinogens by acting as a solvent for entrance into the mucosal tissues.  As a 
result, using alcohol with other drugs can have synergistic effects.  Previous studies 
suggest that the effects of alcohol and smoking are multiplicative.  About 75% of 
aerodigestive tract carcinomas can be credited to the simultaneous use of alcohol and 
tobacco.  In addition, various in vivo and in vitro studies suggest that the metabolic 
byproduct of alcohol, acetaldehyde, possesses toxic effects.  Acetaldehyde has the ability 
to disrupt DNA synthesis, DNA repair sites, and the checkpoints involved in cell 
replication.  Therefore, ethanol and acetaldehyde synergistically promote cancer 
development(20,29). 
The chemicals in tobacco smoke are also associated with cancer, producing 
damaging effects on DNA.  Benzo(a)pyrene, which binds to cells in the airways and 
organs of smokers, has been shown to be the most damaging carcinogen in tobacco smoke.  
Consequently, lung cancer is frequently attributed to smoking.  The risk of developing lung 
cancer is directly associated with the number of cigarettes smoked.  Other carcinomas, 
such as cancers of the bladder, kidney, cervix, oral cavity, stomach, pancreas and 
esophagus, are also linked to tobacco use(19).         
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Figure 1: Cancer Rates Attributable to Smoking.  The percentage of various cancers 
caused by smoking.  The upper aerodigestive tract is most affected(19). 
 
Ultraviolet (UV) radiation from the sun can lead to the development of various skin 
cancers, such as cutaneous malignant melanoma, basal cell carcinoma, and squamous cell 
carcinoma.  UV radiation can be divided into three categories (UV-A, UV-B, and UV-C).  
UV-A and UV-B are usually linked with the development of skin carcinomas in humans.  
UV-B has the ability to cause direct damage to DNA through the formation of pyrimidine 
dimers.  Whenever DNA repair mechanisms fail, the resulting mutations can propagate to 
future cell generations via cell divisions.  UV-B can also form highly reactive oxygen 
species (ROS) and damage DNA.  Furthermore, UV-A and UV-B radiation can promote 
the expression of anti-apoptotic proteins.  Although preventable, the frequency of skin 
cancer and mortality has been increasing over the last 10 years(3,30). 
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1.2: Lung Cancer Cell Carcinoma 
Lung Cancer Cell Carcinoma (LCCC) is the second most common malignancy in 
the United States; it is estimated that over 228,000 new cases will arise this year.  The 
majority of lung cancers originate from epithelial cells that line the air passages in the 
lungs.  The two most common types of lung cancer are classified based on their 
histological appearance: small cell lung cancer (SCLC) and non-small cell lung cancer 
(NSCLC).  SCLC accounts for about 12.5% of lung cancer cases.  These cells tend to grow 
aggressively and metastasize quickly.  In contrast, NSCLC is responsible for about 87.5% 
of lung cancer cases.  Compared to SCLC, these cells are larger in size and develop more 
slowly(18).  Additionally, studies have shown that the long-term use of tobacco products 
accounts for 90% of lung cancers(5).  However, it is possible for non-smokers to develop 
lung cancer as well.  Non-smokers may tumors develop due to genetic factors, secondhand 
smoke, air pollution, radon gas, and asbestos(5,24). 
LCCC treatments are tailored based on the stage and type of lung cancer.  In the 
early stages, the cancer is localized to one side of the chest.  If the cancer is aggressive or 
advanced, it commonly spreads to the lymph nodes and other organs.  Lung cancer patients 
with an early diagnosis may be eligible for surgical removal of the primary tumor.  In 
addition, radiotherapy and chemotherapy are other options available at any stage of the 
disease(18).  Admittedly, lung cancer is difficult to control with current treatments.  In 
addition, only 15% of patients are diagnosed at an early stage.  As a result, the 5-year 
prognosis remains poor.  Previous research shows that the overall 5-year survival rate for 
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2002-2008 was 15.9%(9).  Therefore, it is evident that new, viable treatments are necessary 
to improve patient survival. 
 
Table 1: Lung Cancer Stage Distribution and 5-year Survival.  The average 5-year 
survival rate of cancer patients is compared to that of the general population.  The majority 
of patients are diagnosed when the cancer has advanced to later stages(9). 
.   
1.3: p53 and its Effects on Cancer 
Protein 53 (p53) is a well-known tumor suppressor that regulates the cell cycle and 
apoptosis in multicellular organisms.  In humans, it is encoded by the TP53 gene located 
on chromosome 17(16,10).  Due to its role in maintaining genomic stability, p53 has been 
described as "the guardian of the genome"(21).  The p53 protein is made of 393 amino 
acids, and has four domains:  a domain that activates transcription(26), a core domain that 
binds DNA(12), a domain involved in the tetramerization of p53(6), and a domain that 
recognizes damaged DNA(4). 
In normal cells, the expression p53 protein is low.  However, cellular stresses, such 
as DNA damage, may increase its production.  A rise in p53 expression leads to growth 
arrest at the G1/S regulation point in the affected cells, which in turn prevents the 
replication of damaged DNA.  During cell cycle arrest, p53 also activates genes that 
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produce DNA repair proteins.  Once the DNA is repaired, cell cycle inhibition comes to an 
end.  However, if the DNA is irreparable, p53 can initiate apoptosis in the damaged cells.  
In this manner, the proliferation of cells with abnormal DNA is prohibited(2). 
Due to the fact that p53 causes potent downstream effects, its expression needs to 
be regulated.  Although it can inhibit tumor growth, high levels of p53 may cause 
unnecessary apoptosis and result in premature aging.  A regulatory gene, Mdm2, functions 
to regulate the expression of p53.  As p53 becomes activated, the expression of Mdm2 is 
also increased.  Mdm2 then downregulates the expression of p53 by labeling it for 
degradation with ubiquitin(2). 
 
 
Figure 2: Simplified Scheme of the p53 Pathway.  Cellular stress leads to increased 
expression of p53, which in turn activates downstream genes involved in growth arrest, 
DNA repair, and apoptosis.  Increased p53 expression leads to increased Mdm2 
expression, which in turn negatively regulates p53(14). 
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Defective p53 can result in the reduction of tumor suppression and lead to tumor 
formation.  In over 50% of all cancers, the p53 gene is either mutated or deleted, resulting 
in the expression of a non-functional mutant p53 protein.  This loss-of-function mutation 
results in the deregulation of the cell cycle and apoptosis, which may lead to the 
uncontrolled growth of cells.  Previous research also implies that p53 plays a role in cell 
migration and invasion.  In addition, recent studies suggest that gain-of-function mutations 
may occur in p53, which may play a role in promoting cell migration, invasion, and 
metastasis(17). 
The numerous studies on p53 have led to the increased understanding of processes 
involved in tumorigenesis.  Although cancer therapies have yet to be derived from these 
findings, it is clear that p53 is a powerful mediator of various cell functions, and that the 
formation of most tumors is dependent on the inactivation of p53.  In effect, this makes 
p53 a valuable target for cancer treatment. 
 
1.4: Tarsh and Cellular Senescence in Lung Cancer 
Cellular senescence, or aging, is an unavoidable process that all cells in the body 
eventually undergo.  It was predominantly observed in cultured human fibroblast cells that 
entered an irreversible non-dividing state.  Recent studies have reported that the shortening 
of telomeres may contribute to this process.  Furthermore, these studies have also shown 
that senescence could be stimulated by extrinsic factors unrelated to telomere length.  
These factors included oxidative stress, UV exposure, and oncogenic gene activation.  The 
role of other senescence-related genes, such as p53, has been investigated, though not 
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much is known about the overall process of senescence at this point.  However, these 
studies suggest that senescence is likely involved in the elimination of damaged cells, 
which in turn suppresses tumor formation(25). 
Recent findings suggest that Tarsh, a novel target of NESH-SH3, is a molecule 
involved in the regulation of senescence.  Lung carcinomas were specifically chosen 
because the presence of Tarsh was detected in mouse lung.  It was also determined that 
Tarsh expression increased during senescence of mouse embryonic fibroblasts (MEFs)(25).  
Other results have indicated that Tarsh is strongly expressed in normal lung cells, and that 
Tarsh is significantly downregulated in lung tumors.  This downregulation in expression 
coincided with a decrease in a tumor’s ability to proliferate and invade surrounding areas.  
These results suggest that the loss of Tarsh in lung cancer cells may contribute to 
tumoriogenesis(23). 
 
 
Figure 3: Tarsh Expression in 15 Lung Cancer Strains.  The relative mRNA expression of 
Tarsh in various lung cancer cell lines, compared to that of normal lung cells.  A 
significant reduction in Tarsh expression was observed in all 15 strains(23). 
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1.5: Interactions Between p53 and Tarsh 
Another study investigated a possible link between Tarsh and p53 by using a 
senescence-associated β-galactosidase (SA-β-gal) activity assay in MEFs.  Stained cells 
would indicate that the cells were aging.  In preparation for this assay, the expression of 
Tarsh was knocked down in previously derived wild type (WT) and p53 knockdown (KD) 
MEFs.  These cells were then compared to WT and p53 KD MEFs with normal Tarsh 
expression.  The results of this study indicated that TARSH suppression lead to a decrease 
in the staining of MEFs, and therefore reduced cellular senescence(28). 
The same study also examined the effects of Tarsh suppression on various cancer 
related genes.  Other than p53, only one other gene was activated in response to the 
downregulation of Tarsh.  It was determined that p21, a known p53-dependent cyclin-
dependent kinase inhibitor (CKI), was increased in Tarsh-depleted cells(28). Generally, p21 
suppresses cell growth via the induction of cell cycle arrest and the inhibition of gene 
transcription and apoptosis.  These anti-proliferative properties are important in promoting 
cellular senescence(1).  However, an increase in p21 activity was only observed in WT 
MEFs, which expressed p53.  No increase in p21 was detected in p53 KD MEFs(28).  These 
results imply that Tarsh plays a role in p53-dependent cellular senescence in MEFs. 
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Figure 4: Tarsh Expression in p53 KD MEFs.  The relative mRNA expression of Tarsh in 
p53 KD MEFs, compared to that of WT MEFs.  A significant reduction in Tarsh 
expression was observed in p53 KD MEFs(kunihiko). 
 
1.6: Implications of Tarsh in Lung Cancer 
As previously discussed, lung cancer is one of the leading causes of mortality in the 
United States. The 5-year survival rate for lung cancer patients is very low, which can be 
attributed to the fact that its diagnosis usually occurs in later stages.  Therefore, there is a 
dire need to develop effective methods for the early diagnosis and treatment of lung 
cancer.  Recent studies have demonstrated a significant reduction in the expression of 
Tarsh in lung tumors.  This information may prove to be beneficial in clinical applications; 
measurements of Tarsh expression in patients could be utilized to determine if cells have 
become malignant.  In addition, further investigation into the mechanisms of how Tarsh 
contributes to cellular senescence could lead to the development of novel therapies. 
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1.7: Hypothesis and Rationalization for the Current Study 
The rationalization for this study is to further investigate the biological roles of 
Tarsh and p53 in various lung cancer cell lines.  These cell lines include A549 Wild-Type 
(WT) cells, A549 p53 KD (Knockdown) cells, and H1299 cells.  This study will examine 
in vitro proliferation and migration rates of these cells, which express varying levels of 
p53, depending on the cell line.  In turn, the study will verify the effectiveness of Tarsh in 
regards to tumor suppression, while determining its dependency on p53.  The hypothesis of 
this study is that the overexpression of Tarsh will reduce cancer-development related 
processes, such as cell proliferation, motility, and survival.  In addition, based on previous 
findings, it is hypothesized that Tarsh is dependent on the presence of p53, and that the 
effects of Tarsh and p53 may be synergistic. 
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Materials and Methods 
 
 
2.1: Cell Lines and Culture 
 
2.1.1: Cell Line Preparation 
A549 adenocarcinomic human alveolar basal epithelial cells were originally 
obtained from a 58-year-old Caucasian male patient (explanted tumor), and H1299 human 
non-small cell lung carcinoma cells were extracted from a 43-year-old Caucasian male 
patient (lymph node).  The cells were purchased from commercial vendors, and were 
frozen at -80°C.  When ready for use, the cells were placed in a 37°C water bath to thaw.  
The cells were then suspended in a solution of 10 mL of Dulbecco’s modified Eagle’s 
medium (DMEM) (Mediatech, Manassas, VA), 10% Fetal Bovine Serum (FBS), and 
specific antibiotics depending on the cell line.  The A549 WT and H1299 cell medium was 
treated with 100 µg/mL streptomycin, 100 µg/mL neomycin, and 100 µg/mL puromycin.  
The A549 p53 KD cell medium was treated with 100 µg/mL streptomycin and 100 µg/mL 
puromycin.  Afterward, the cells were placed on 10 cm tissue culture plates.  Each tissue 
culture plate was placed in a humidified incubator at 37°C with a 10% CO2 control and 
90% air to allow for growth.  The cells were washed with phosphate-buffered saline (PBS), 
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and cultured in the same media solution every two to three days for maintenance until 
needed. 
 
2.1.2: Transfection of Tarsh and Knockdown of p53 
To establish cell lines overexpressing Tarsh, 10 µg of DNA construct was 
transfected into 5 × 106 A549 WT, A549 p53 KD, and H1299 cells by electroporation 
using a Gene Pulser II (Bio-Rad Laboratories Inc.).  To create controls for each cell type, a 
pcDNA3.1 vector was transfected into these cells.  The resulting clones were isolated after 
three weeks of selection in neomycin and puromycin selection media.  These cells were 
then seeded onto 10 cm plates and incubated to allow for cell expansion.  For each cell 
line, the expression of Tarsh was determined with quantitative real-time polymerase chain 
reaction analysis (qRT-PCR). 
p53 knockdown in A549 WT and A549 WT Tarsh transfected cells were generated 
by using lentivirus expressing short hairpin RNA (shRNA) against p53.  Lentivirus 
systems (Open Biosystems) were utilized, following the manufacturer’s protocol.  Clones 
were isolated after three weeks of selection in neomycin and puromycin selection medium.  
These cells were then seeded onto 10 cm plates and incubated to allow for cell expansion.  
For each cell line, the expression of p53 was determined with qRT-PCR. 
 
2.1.3: Cell Maintenance 
Once the cells reached 100% confluency, they were split.  The each cell plate was 
washed twice with 10 mL PBS, and then 1 mL of 0.5% trypsin was added. The cells were 
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then incubated for 5-15 minutes for detachment.  To ensure proper detachment from the 
plate, the detachment of cells after administration of trypsin were confirmed with the 
microscope.  Afterward, the cells were incubated to allow for continued healthy expansion. 
 
2.1.4: Cell Stock Preparation 
 Long-term storage of cell lines was prepared by making cell stock solutions in 
cryovials.  5 mL of media was added via jet flow to each 10 cm plate of cells after 
detachment with 1 mL of 0.5% trypsin.  The cell-media solution was then collected, 
pipetted into a 15 mL vial, and centrifuged at 800 rpm for 5 minutes at 4 degrees Celsius.  
After centrifugation, the media supernatant was removed by aspiration, leaving a cell pellet 
intact.  The pellet was lightly tapped and 2 mL of Bambanker serum-free cell freezing 
medium (Lymphotec Incorporated, Tokyo, Japan) was added to form a suspension.  With 
each 2 mL suspension, 4-5 cryovials were produced and placed in an -80°C freezer for 
later use. 
 
2.2: Reagents and Antibodies 
 For use in western blot experiments, the following items were purchased from 
commercial vendors: mouse monoclonal p53 primary detection antibodies (Santa Cruz 
Biotechnology Incorporated, Catalog Number: sc-126, Lot H1903S), rabbit monoclonal α-
tubulin primary detection antibodies (Cell Signaling Technology Incorporated, Catalog 
Number: 2125S, Lot 11H10), anti-rabbit IgG secondary detection antibodies (Cell 
Signaling Technology Incorporated, Catalog Number: 7074), and anti-mouse IgG 
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secondary detection antibodies (Cell Signaling Technology Incorporated, Catalog Number: 
7076). 
 
2.3: RNA Extraction 
RNA was extracted from 60 mm plates at 80% confluency using an RNeasy Mini 
Kit with RNeasy spin columns, QIAGEN® Shredder, and RNase-Free DNase Set 
according to protocol provided by the manufacturer (QIAGEN® Incorporated).  The RNA 
was then stored at -80°C until it was needed.  The purity of the RNA was confirmed by 
using the NanoDrop ND-1000 spectrophotometer with 1 µL of RNA sample (Thermo 
Fisher Scientific).  
 
2.4: Reverse Transcription 
Complementary DNA (cDNA) was produced using the High Capacity cDNA 
Reverse Transcription achieve kit (Applied Biosystems).  To produce cDNA, 1 µg of RNA 
was reverse-transcribed with a total volume of 20µL of 2X RT Master Mix (10x reverse 
transcriptase buffer, 25x deoxyribonucleotide triphosphate mix, 10x RT random primer, 
MultiScribeTM reverse transcriptase, RNase inhibitor, and nuclease-free water).  A four-
step reaction was conducted in a thermal cycler:  10 minutes at 25°C, 120 minutes at 37°C, 
5 minutes at 85°C, and infinite minutes at 4°C.  The generated cDNA was then stored at -
20°C for later use. 
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2.5: Quantitative Real-Time Polymerase Chain Reaction Analysis (qRT-PCR) 
qRT-PCR is a method utilized to measure mRNA expression in cells.  Previously 
generated cDNA is needed for this assay, and is obtained from the Reverse Transcription 
assay, as described in chapter 2.4.  Taqman® qRT-PCR was performed using primers to 
the two genes of interest (Tarsh and p53), and also the housekeeping gene glyceraldehyde-
3-phosphate-dehydrogenase (GAPDH).  GAPDH served as a positive homogenous control.  
Taqman® Gene Expression Assay primer Mm00618913_m1 for Tarsh (Applied 
Biosystems), primer Hs01034249_m1 for p53 (Applied Biosystems), and Taqman® 20x 
GAPDH primer probe dye: FAM-MGB (Applied Biosystems) were utilized.   
The qRT-PCR reaction was carried out in triplicate on a 96-well optical reaction 
plate.  Each well was comprised of 5 µL cDNA, 10 µL Taqman® 2x Universal PCR Master 
Mix (Applied Biosystems), 1 µL 20x primer, 4 µL distilled water, for a total volume of 20 
µL/well.  Afterward, the GAPDH primers were diluted to a 1:10 ratio.  The plate was then 
sealed with a self-adhesive optical cover, and placed into the qRT-PCR machine. 
The cDNA was then amplified using the 7500 HT Fast Real-Time PCR System 
(Applied Biosystems).  The process involved the following steps: activation for two 
minutes at 50°C, then denaturation for 20 seconds at 95°C, followed by 40 cycles of 
melting for three seconds at 95°C, and finally annealing/extending for 30 seconds at 60°C, 
respectively.  Using SDS 2.2 software, the average ΔΔCT values were calculated and 
relative quantification (ΔRQ) was measured.  Finally, the difference in ΔRQ values 
between the targets and GAPDH was calculated. 
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2.6: Western Blot Assay 
Cellular proteins from each cell line were extracted from cultured cells.  These 
proteins were resolved in 12% denaturing polyacrylamide gels with 0.1% SDS.  The 
proteins were resolved for 1 hour and 30 minutes at 125 V in 1x SDS-PAGE running 
buffer.  Next, the proteins were transferred onto a polyvinylidene difluoride membrane 
(BioRad Laboratories) after it was briefly soaked 100% methanol.  The transfer occurred in 
a 1x transfer buffer solution at 8 mA, and was run overnight. 
After the transfer was completed, it was necessary to block the membrane.  The 
membrane was gently rocked in a solution comprised of 2.5 g of dry milk dissolved in 50 
mL of 1x Tris-Buffered Saline and Tween-20 (TBST) for 30 minutes.  The membrane was 
then was washed three times for 5 minute periods.  Afterward, the primary antibody was 
diluted in a 5% TBST/milk or 1% bovine serum albumin (BSA) solution to generate a 
1:1000 concentration.  The membrane was gently rocked overnight at 4°Cl.  Next, the 
membrane was washed three times for 5 minutes each in TTBS.  Adding the antibody to a 
TBST/milk solution produced a 1:10,000 secondary dilution.  The membrane was then 
gently rocked in this solution for 1 hour at room temperature.  The membrane was washed 
for two 10-minute periods and one 30-minute period in TTBS. 
Next, the membrane was prepared for film exposure by placing the membrane in a 
solution comprised of 500 µL of enhancer solution and 500 µL of peroxide buffer for five 
minutes (Western Lightning Chemiluminescence Plus System).  The membrane was then 
wrapped in saran wrap, placed inside a cassette, and taken to a dark room.  Blue Devil 
autoradiography film (Genesee Scientific) was placed onto the membrane and the cassette 
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was closed for a specific amount of time, depending on the primary antibody used.  
Finally, the film was placed into a Kodak photo-processing developer machine for 
exposure. 
 
2.7: Cell Proliferation Assay 
 In preparation for this experiment, cultured cells were allowed to reach between 40-
60% confluency on 10 cm plates.  Cells were then washed twice with 5 mL PBS, and then 
detached from their culture plates using 1 mL of trypsin and placing the cells in a 37°C 
incubator for 15 minutes.  These cells were seeded in triplicate in 24-well cell culture 
plates, and diluted to a density of 2 x 103 cells/mL in medium.   The cells were then placed 
in a 37°C incubator for a 24-hour growth period. 
Following the initial growth period, the first triplicate was washed twice with 1 mL 
of PBS.  After aspiration of the PBS, 200 µL of trypsin was pipetted into each well.  The 
cells were then placed back into the incubator for 15 minutes to allow for cell detachment.  
After detachment, cells from each well were placed into separate eppendorf tubes.  A 20 
µL volume from each eppendorf tube was then pipetted into a hemocytometer (Improved 
Neubauer Haemocytometer) chamber for cell counting.   
The hemocytometer was then placed under a light microscope, and cells were 
found to reside in a nine-box grid.  Counting of the cells was performed in each of the four 
corner grids (Figure 10).  An average number of cells per well was obtained by dividing 
the total number of counted cells by four.  This was repeated for all three samples for each 
cell derivative.  These steps were repeated daily, for a total of six days.  After the end of 
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the assay, the data was compiled in Excel and a proliferation curve was generated for each 
cell line.  Tarsh transfected cells were compared to their respective controls to determine 
the effects of Tarsh on proliferation.  Similarly, A549 p53 KD cells were compared to 
A549 WT cells to ascertain the effects of p53 on proliferation. 
 
           
 
 
 
 
2.8: Cell Migration Assay 
 In preparation for this experiment, cultured cells were allowed to reach between 40-
60% confluency on 10 cm plates.  Cells were then washed twice with 5 mL PBS, and then 
detached from their culture plates using 1 mL of trypsin and placing the cells in a 37°C 
incubator for 15 minutes.  These cells were seeded in triplicate in 24-well cell culture 
Figure 5: Hemocytometer Counting.  Cell counting was performed in the four 
areas indicated by the arrows.   
 
   
 21 
plates, and diluted to a density of 2.5 x 105 cells/mL in medium.   The cells were then 
placed in a 37°C incubator for a 24-hour growth period.   
After the growth period, a sterile P200 pipette tip was utilized to create a scratch 
wound across each well (from top to bottom) in the 24-well plate.  The scratch distance 
was measured at the time of the scratch (time = 0 hours).  A ZEISS® Axiovert 200M 
microscope with AxioVision® digital image processing software was utilized to capture 
scratch distances in two different areas each scratch.  Cells were then incubated for eight 
hours, resulting in the migration of cells and a reduction in the size of the scratch.   
At the end of the incubation period (time = 8 hours), images were captured at the 
same two areas in each well.  Each image at time = 8 hours was compared to its respective 
image at time = 0 hours.  Tarsh transfected cell lines were compared to their respective 
controls to determine the effects of Tarsh on migration.  Similarly, A549 p53 KD cells 
were compared to A549 WT cells to ascertain the effects of p53 on migration.  To 
calculate the difference in migration, the following formula was used: 
 
𝑀𝑖𝑔𝑟𝑎𝑡𝑖𝑜𝑛  𝑅𝑎𝑡𝑒 = 𝑆𝑐𝑟𝑎𝑡𝑐ℎ  𝑑𝑖𝑠𝑡𝑎𝑛𝑐𝑒  𝑎𝑡  0  ℎ𝑜𝑢𝑟𝑠 − (𝑆𝑐𝑟𝑎𝑡𝑐ℎ  𝐷𝑖𝑠𝑡𝑎𝑛𝑐𝑒  𝑎𝑡  8  ℎ𝑜𝑢𝑟𝑠)𝑆𝑐𝑟𝑎𝑡𝑐ℎ  𝐷𝑖𝑠𝑡𝑎𝑛𝑐𝑒  𝑎𝑡  0  ℎ𝑜𝑢𝑟𝑠 ∗ 100% 
 
2.9: Statistical Analysis 
 Comparisons between two groups were analyzed by using an unpaired t-test 
analysis with Excel and GraphPad software.  A p-value < 0.05 was considered to be 
statistically significant. 
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Results 
 
 
3.1: Tarsh Expression Confirmation with qRT-PCR Analysis 
To investigate the biological role of Tarsh in A549 WT, A549 p53 KD, and H1299 
cell carcinomas, the mRNA expression of Tarsh was examined in Tarsh transfected cell 
lines.  For all of the cell types, BEAS-2B cells (normal epithelial lung cells) were used as a 
baseline for comparison.  This information was needed before subsequent experiments 
could be performed to determine the effects of Tarsh on survival, proliferation, and 
migration. 
In all of the lung cancer cell lines, all control cells were found to have a negligible 
expression of Tarsh.  A549 WT Tarsh transfected cells were found to have 9.2% greater 
Tarsh expression, when compared to BEAS-2B cells.  A549 p53 KD Tarsh transfected 
cells displayed a 66.3% reduction in Tarsh expression, when compared to BEAS-2B cells.  
Tarsh expression of H1299 Tarsh transfected cells was reduced by 56.7%, when compared 
to BEAS-2B cells.  All of these differences were observed to be significant (Figure 6). 
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* p < 0.05, **** p < 0.0001 
 
Figure 6: Tarsh Expression.  RNA was extracted from near-confluent cultures of BEAS-
2B, A549, and H1299 cells and reverse transcribed.  Afterward, qRT-PCR was performed 
as previously described in Materials and Methods.  Tarsh expression was standardized to 
the GAPDH, the homogenous control.  The PCR was performed in triplicate and relative 
means ±SEM are shown.  A statistically significant decrease in Tarsh expression was 
found in A549 WT control cells, A549 p53 KD control cells, and H1299 control cells.  
A549 WT Tarsh transfected cells, A549 p53 KD Tarsh transfected cells, and H1299 Tarsh 
transfected cells displayed Tarsh expression within physiological ranges, thus confirming 
that any future experiments with these cell lines will be physiologically relevant. 
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3.2: p53 Downregulation Confirmation with qRT-PCR Analysis 
To investigate the biological role of p53 in A549 WT, A549 p53 KD, and H1299 
cell carcinomas, the mRNA expression of p53 was examined in these lung cancer cell 
lines.  For all of the cell types, the A549 WT control cells were used as a baseline for 
comparison.  This information was needed before subsequent experiments could be 
performed to determine the effects of p53 on survival, proliferation, and migration. 
A549 WT Tarsh transfected cells were found to have 38.1% higher levels of p53 
expression compared to the A549 WT control cells.  However, this was not found to be 
statistically significant and was considered to be similar to the baseline.  Both A549 p53 
KD control cells, and A549 p53 KD Tarsh transfected cells showed a significant decrease 
in p53 expression, with an 81.6% reduction (Figure 7).  
Similarly, both H1299 control cells and H1299 Tarsh transfected cells displayed a 
significant decrease in p53 expression, with a 75% reduction (Figure 7).  Although this 
PCR experiment suggests that some p53 expression is still present in H1299 cells, this is 
not true of H1299 cells.  As confirmed by previous findings(15), and by the western blot to 
be discussed in the next section, these cells do not produce any functional p53 protein.  
This discrepancy can be explained by the fact that the p53 probe used in this experiment is 
detecting the partially deleted p53 gene in these cells. 
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** p < 0.01 
 
Figure 7: p53 Gene Expression.  RNA was extracted from near-confluent cultures of A549 
and H1299 cells and reverse transcribed.  Afterward, qRT-PCR was performed as 
previously described in Materials and Methods.  The p53 expression was standardized to 
the GAPDH, the homogenous control.  The PCR was performed in triplicate and relative 
means ±SEM are shown.  A statistically significant decrease in p53 expression was found 
in A549 p53 KD cell lines and H1299 cell lines, when compared to A549 WT control 
cells. 
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3.3: p53 Protein Expression Confirmation with Western Blot 
To validate the previous results of the qRT-PCR in regards to p53 (Figure 2), it was 
necessary to perform a western blot analysis.  A549 WT, A549 p53 KD, and H1299 cells 
were lysed, and gel electrophoresis was performed.  The proteins were then transferred 
onto a membrane, which were detected with specific antibodies.  This protocol was 
previously described in Materials and Methods.  In this experiment, α-tubulin was used as 
the control. 
The results of this experiment confirm the previous results of the qRT-PCR in 
regards to p53.  It is clear that p53 protein expression levels in A549 WT cells are similar 
to that of tubulin.  In addition, p53 protein expression is significantly downregulated in 
A549 p53 KD cell lines.  In regards to H1299 cell lines, the western blot shows that these 
cells are not producing p53 protein (Figure 8). 
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Figure 8: Western Blot Analyzing p53 Protein Expression.  A549 WT, A549 p53 KD, and 
H1299 cells were lysed and gel electrophoresis was performed.  The proteins were 
subsequently transferred to a membrane, and specific antibodies were utilized to determine 
the total molecule content of tubulin and p53.  Tubulin was the control in this experiment.  
A549 WT cell lines had a comparable amount of p53 protein to tubulin.  A549 p53 KD cell 
lines displayed a significant reduction in p53 protein production.  H1299 cell lines did not 
produce p53 protein.  Three trials were performed for this experiment. 
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3.4: Tarsh Overexpression Suppresses Proliferation in All Cell Lines 
The proliferation and growth of cells in lung cancer contribute to the progression 
and metastasis of the disease.  Therefore, it was important to observe the proliferation rates 
of all the cell lines involved in the study.  Once the stability of the Tarsh transfected cell 
lines was confirmed by qRT-PCR (Figure 6), the cells were prepared for cell proliferation 
assays to measure their growth rates.  In these assays, each cell line’s respective control 
vector served as a basis for comparison.  Each cell line was diluted to a density of 5 x 103 
cells/mL in its respective selection medium conditions.  The cells were then plated, in 
triplicate, onto 24-well plates (though only 18 wells were needed).  A 24-hour latency 
period was allowed for initial growth to occur.  For the following six days, cells in three 
out of the 18 wells were trypsinized and counted.  The triplicated results were then 
averaged. 
As shown in Figure 9, A549 WT Tarsh transfected cells exhibited an average 
reduction of 38% in growth when compared to A549 WT control cells.  Starting from day 
3, a statistically significant difference was observed with a p-value < 0.05.  From days 4-6, 
the difference was extremely significant, with a p-value < 0.0001.  Similarly, the average 
proliferation of A549 p53 KD Tarsh transfected cells was reduced by about 40% when 
compared to A549 p53 KD control cells (Figure 10).  This decrease was also found to be 
statistically significant starting from day 2.  Finally, Figure 11 shows that Tarsh also 
suppresses proliferation rates in H1299 cell lines.  H1299 Tarsh transfected cells exhibited 
an average reduction of about 33% in growth when compared to H1299 control cells.  The 
difference in growth was considered to be statistically significant. 
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* p < 0.05, **** p < 0.0001 
 
Figure 9: A549 WT Proliferation.  A549 WT cells were diluted to a density of 2 x 103 
cells/mL and were allowed a 24-hour growth period before counting began.  In each trial, 
the cells were seeded in triplicate.  An average number of cells were calculated each day 
for a total of six days.  The mean cell counts and the ±SEM are shown.  Starting from day 
3, a significant reduction in proliferation was observed in A549 WT Tarsh transfected cells 
when compared to A549 WT control cells.  The number of trials ranged from six to seven 
for each cell line. 
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* p < 0.05, ** p < 0.01, *** p < 0.001, **** p < 0.0001 
 
Figure 10: A549 p53 KD Proliferation.  A549 p53 KD cells were diluted to a density of 2 
x 103 cells/mL and were allowed a 24-hour growth period before counting began.  In each 
trial, the cells were seeded in triplicate.  An average number of cells were calculated each 
day for a total of six days.  The mean cell counts and the ±SEM are shown.  Starting from 
day 2, a significant reduction in proliferation was observed in A549 p53 KD Tarsh 
transfected cells when compared to A549 p53 KD control cells.  The number of trials 
ranged from three to five for each cell line. 
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* p < 0.05, ** p < 0.01, **** p < 0.0001 
 
Figure 11: H1299 Proliferation.  H1299 cells were diluted to a density of 2 x 103 cells/mL 
and were allowed a 24-hour growth period before counting began.  In each trial, the cells 
were seeded in triplicate.  An average number of cells were calculated each day for a total 
of six days.  The mean cell counts and the ±SEM are shown.  A significant reduction in 
proliferation was observed in H1299 Tarsh transfected cells when compared to H1299 
control cells.  Six trials were performed for each cell line.  
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3.5: p53 Downregulation Increases Proliferation in All Cell Lines 
In addition to observing the effects of Tarsh on cell growth, it was also important to 
determine the effects of downregulating p53 on the proliferation rates of all the cell lines 
involved in the study.  A direct comparison between A549 WT and A549 p53 KD cells 
cannot be made due to differing selection medium conditions between the two.  However, 
it can be inferred from the results that reducing p53 expression via knockdown in A549 
cells increases proliferation, as A549 WT cells (Figure 9) generally had a higher cell count 
than A549 p53 KD cells (Figure 10).  Similarly, although a direct comparison between 
A549 WT cells and H1299 cells cannot be made due to the fact that they are different cell 
lines, A549 WT cells (Figure 9) generally had a higher cell count than H1299 cells (Figure 
11).  This implies that the lack of p53 in H1299 cells caused an increase in the number of 
cells. 
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3.6: Tarsh Suppresses A549 Migration, H1299 Migration Unaffected 
In vitro motility studies can give an indication of how readily a cancer metastasizes 
and spreads to distant areas of the body.  Therefore, it was also important to observe the 
effects of Tarsh overexpression on cellular migration, in addition to proliferation.  To 
observe the motility of A549 WT and A549 p53 KD cell lines, migration assay were 
performed.  Each cell line was seeded across six wells, with each well yielding 
quadruplicate measurements.  Each cell line was diluted to a density of 2.5 x 105 cells/mL, 
and the cells were allowed to grow to 100% confluency.  A scratch was made on each well, 
and the cells were then incubated for eight hours.  At the end of the incubation period, the 
cellular migration was calculated using AxioVision® software (Figure 12). 
A549 WT Tarsh transfected cells displayed a statistically significant reduction in 
migration compared to A549 WT control cells.  The difference in migration was 18.5%, 
with a p-value < 0.01.  Similarly, A549 p53 KD Tarsh transfected cells displayed a 
statistically significant reduction in migration compared to A549 p53 KD control cells.  
The migration was reduced by 18.2%, and the p-value was less than 0.05 (Figure 13). 
However, Tarsh overexpression did not have any effect on H1299 cell migration.  
With a difference of only 1.4%, there was no statistically significant reduction when 
comparing H1299 Tarsh transfected cells to H1299 control cells (Figure 14). 
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Figure 12: Cell Migration Assay.  A549 WT and A549 p53 KD cells were plated at a 
density of 2.5 x 105 cells/mL, and were allowed to reach 100% confluency in their 
respective selection medium conditions.  The migration assay was performed at time = 0 
hours.  After an 8-hour incubation period, the migration distances were measured with a 
ZEISS® Axiovert 200M microscope and AxioVision® digital imaging software.  
Representative images of A549 WT cells are shown at 0 and 8 hours. 
A549 WT Control, 
time = 0 hours 
A549 WT Control, 
time = 8 hours 
 
A549 WT Tarsh, 
time = 0 hours 
 
A549 WT Tarsh, 
time = 8 hours 
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* p < 0.05, ** p < 0.01 
 
Figure 13: Role of Tarsh in A549 Migration.  A549 cells were diluted to a density of 2.5 x 
105 cells/mL and cultured to confluency.  In each trial, the cells were seeded in 
quadruplicate.  After reaching confluency, a migration assay was performed.  A cell 
retardation ratio was then calculated based on the migration distance after 8 hours.  The 
ratios were then averaged and the ±SEM for each cell line was calculated.  A549 WT 
Tarsh transfected cells displayed a significant reduction in migration compared to A549 
WT control cells.  Similarly, A549 p53 KD Tarsh transfected cells displayed a significant 
reduction in migration compared to A549 p53 KD control cells.  The number of trials 
ranged from five to six for each cell line. 
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Figure 14: H1299 Migration.  H1299 cells were diluted to a density of 2.5 x 105 cells/mL 
and cultured to confluency.  In each trial, the cells were seeded in quadruplicate.  After 
reaching confluency, a migration assay was performed.  A cell retardation ratio was then 
calculated based on the migration distance after 8 hours.  The ratios were then averaged 
and the ±SEM for each cell line was calculated.  No significant difference in migration was 
observed between the two cell lines.  The number of trials ranged from four to five for 
each cell line. 
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3.7: Role of p53 in Migration is Unclear 
In addition to Tarsh, it was also necessary to observe the effects of p53 
downregulation on cellular motility.  A direct comparison between A549 WT and A549 
p53 KD cells cannot be made due to differing selection medium conditions between the 
two.  However, it can be inferred from the results that reducing p53 expression via 
knockdown in A549 cells decreases the migration rate, as A549 p53 KD cells generally 
had a reduced migration distance when compared to A549 WT cells (Figure 13). 
However, the opposite was observed when comparing A549 WT cells to H1299 
cells.  Although a direct comparison between A549 WT cells and H1299 cells cannot be 
made due to the fact that they are different cell lines, H1299 cells (Figure 14) generally had 
a higher migration distance when compared to A549 WT cells (Figure 13).  In this case, 
the results imply that reducing p53 expression in cells increases the migration rate. 
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Discussion 
 
4.1: Aims of the Current Study 
The conclusions made by previous studies have shown that Tarsh expression is 
often downregulated in various cancer cell lines, and that re-expression of Tarsh 
significantly reduces cell proliferation, migration, and survival(13,24,28).  These results 
suggest that the loss of Tarsh expression may play a vital role in the pathogenesis and 
progression of various types of cancers.  In addition, a previous paper concluded that Tarsh 
is dependent upon p53, suggesting that without it, Tarsh may lose its effectiveness(12).  
However, only a very limited number of studies have been published, and further 
investigation is needed.  As a result, the combined effects of Tarsh and p53 on tumor 
development are yet to be fully determined. 
 
4.2 The Lung Cancer Cell Carcinoma (LCCC) Model System 
In order to effectively study the effects of Tarsh and p53 in LCCC, an in vitro 
approach was utilized.  Before any experiments were performed, lung cancer cell lines 
   
 39 
were prepared and maintained in culture.  The first cell line was the A549 cell line.  These 
cells were obtained from an explanted tumor of a 58-year-old Caucasian male.  For this 
study, the A549 cell line was split, and one group was transfected with Tarsh.  Each 
resulting group was then split again, and p53 expression was knocked down in each group.  
This procedure resulted in four cell derivatives: A549 WT control, A549 WT Tarsh 
transfected, A549 p53 KD control, and A549 p53 KD Tarsh transfected cells.  The H1299 
cell line was the second cell line, which was isolated from a lymph node metastasis in a 
43-year-old Caucasian male.  These cells were split, and one group was transfected with 
Tarsh, resulting in two derivatives: H1299 Control and H1299 Tarsh transfected cells. 
First, it was necessary to determine the mRNA expression levels of Tarsh in these 
cells, due to the fact that half of the cell derivatives were previously transfected with Tarsh.  
Therefore, qRT-PCR analysis was performed in the aforementioned cell lines.  The results 
of the analysis showed that each Tarsh transfected cell line had significantly higher Tarsh 
mRNA expression when compared to its respective control (Figure 6).  This data provided 
some of the foundation of the current study that was needed before any biological assays 
could be performed. 
It was also essential to determine the expression levels of p53, as its expression was 
knocked down in half of the A549 cell derivatives, and is non-existent in H1299 cells.  For 
this signaling molecule, qRT-PCR and western blot analyses were performed.  In these 
assays, the p53 expression in A549 WT control cells served as the baseline measurement.  
The results of both assays led to the conclusion that p53 expression was highly 
downregulated in both A549 p53 KD control and A549 p53 KD Tarsh transfected cells 
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(Figures 7 and 8).  Similarly, it was shown that both H1299 control and H1299 Tarsh 
transfected cells also had significantly decreased p53 expression (Figures 7 and 8).  
However, in regards to H1299 cells, it must be stated that a discrepancy was observed 
between the two assays.  The qRT-PCR assay suggests that some p53 is present in H1299 
cells, while the western blot analysis suggests that the cells are not generating any p53 
protein.  This can be explained by the fact that the p53 probe used in this experiment is 
detecting the partially deleted p53 gene in these cells. 
 
4.3: Role of p53 and Tarsh in Cell Proliferation 
Previous research has indicated that the expression of Tarsh is downregulated in 
various cancer cells(13,24,28).  In addition, it is common for p53 functionality to be lost in 
cancer, resulting in severely reduced tumor suppression(8).  In turn, cells that express p53 
and Tarsh inhibited cell proliferation(13,27).  Results from the current study indicate that a 
decrease in proliferation was observed due to increased Tarsh and increased p53 
expression.  However, these two genes seem to work independently. 
 Ectopic overexpression of Tarsh in A549 cell lines caused a significant reduction in 
proliferation, when compared to their respective controls (Figures 9 and 10).  In A549 WT 
cells, an average reduction of 38.0% was observed.  Similarly, in A549 p53 KD cells, 
proliferation was reduced by an average of 39.7%.  H1299 cells behaved similarly to A549 
cells; proliferation was reduced by an average of 33.4% in H1299 Tarsh transfected cells 
(Figure 11).  These findings suggest that Tarsh has an inhibitory effect on proliferation, 
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independent of p53.  This is due to the fact that regardless of the level of p53 expression, 
Tarsh was able to downregulate proliferation in all of the examined lung cancer cell lines. 
 Although the effects of p53 on cell proliferation could not be directly compared 
between the cell lines, either due to differing selection medium conditions or the fact that 
the compared groups contained different cell lines, it could be inferred from the data that 
p53 has an inhibitory effect on proliferation.  It can be generalized that A549 p53 KD cells 
had a higher cell count than A549 WT cells due to the fact that its p53 expression was 
knocked down in A549 p53 KD cells.  Similarly, it can also be generalized that H1299 
cells also have a higher cell count because they do not express p53. 
 
4.4: Role of p53 and Tarsh in Cell Migration 
Previous findings suggest that Tarsh and p53 expression suppresses cell motility in 
cancer cells(13,17).  The results of the current study support the notion that Tarsh 
overexpression reduces motility, but only in A549 cells.  However, Tarsh overexpression 
in H1299 cells did not affect migration.  Additionally, a concrete conclusion cannot be 
made in terms of the effects of p53 on migration, due to varying results. 
 The overexpression of Tarsh in A549 cell lines caused a significant reduction in 
migration, when compared to their respective controls (Figure 13).  In A549 WT cells, an 
average reduction of 18.5% was observed.  Likewise, in A549 p53 KD cells, proliferation 
was reduced by an average of 18.2%.  These findings suggest that Tarsh has an inhibitory 
effect on migration, independent of p53.  This is due to the fact that regardless of the level 
of p53 expression, Tarsh was able to downregulate migration in A549 cells. 
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 However, H1299 cell migration was not affected by ectopic Tarsh overexpression; 
only a 1.4% difference in migration was observed (Figure 14).  These results could be 
explained by the fact that H1299 cells do not have functional p53(15), and are therefore 
different from A549 cells.  Due to the complete lack of p53 in H1299 cells, they may lack 
a p53-dependent pathway in which migration is dependent on in A549 cells.  It could be 
possible that H1299 cells have circumvented this pathway, or may have even developed a 
novel pathway that affects migration.  Although p53 expression was highly downregulated 
in A549 p53 KD cells, this was artificially created.  In reality, A549 cells do express 
endogenous p53.  Therefore, it is likely that a p53-dependent pathway still exists in A549 
p53 KD cells. 
Although the effects of p53 on cell migration could not be directly compared 
between the cell lines, either due to differing selection medium conditions or the fact that 
the compared groups contained different cell lines, it could be inferred from the data that 
p53 has opposing effects in A549 cells and H1299 cells.  It can be generalized that A549 
p53 KD cells had a reduced migration rate, when compared to A549 WT cells, due to the 
fact that its p53 expression was knocked down in A549 p53 KD cells.  These observations 
do not support previous findings.  However, it can also be generalized that H1299 cells, 
which lack p53, was observed to have the highest migration rate.  These results do support 
previous findings.  The unexpected results of the A549 p53 KD migration assays could 
possibly be explained by the use of a differing selection medium.  These cells were grown 
in a puromycin selection medium, whereas A549 WT and H1299 cells were grown in a 
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neomycin and puromycin selection medium.  It is possible that the differing conditions 
could have impacted the results. 
 
4.5: Conclusions 
In this study, it was shown that ectopic overexpression of Tarsh in lung cancer cell 
lines decreased cell proliferation and migration, independent of p53.  Additionally, 
decreased p53 expression levels coincided with an increase in cell proliferation.  However, 
the role of p53 in LCCC migration remains unclear.  At this point, a more detailed 
understanding of the pathway by which Tarsh and p53 interact is required to make more 
concrete conclusions.  Regardless of this fact, this field of research seems promising in that 
it may lead to the development of novel treatments that can suppress tumor malignancy. 
 
4.6: Future Studies 
 Given that p53 is mutated in many types of cancer(8), supplemental experiments 
focusing on cell lines with mutated p53 could be utilized.  KNS-62, an epithelial cell line 
derived from a brain metastasis of a primary lung tumor(22), has been prepared for future 
experiments.  Stable Tarsh transfects were produced using the GeneCopoeia® HIV-based 
lentiviral expression vector system.  Tarsh expression was confirmed via qRT-PCR.  The 
resulting cell derivatives, KNS-62 control cells and KNS-62 Tarsh transfected cells, were 
frozen, made into stock, and stored at -80°C.  These cells are ready to be utilized in 
proliferation and migration assays. 
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 In addition, it is necessary to reexamine cell migration in A549 p53 KD cell lines.  
The results obtained from this study do not follow the trend that was observed in previous 
studies, as well as H1299 cells.  As explained in the discussion section, a possible reason 
for this outcome could be due to the selection medium used for A549 p53 KD cells.  
Repeating the migration experiments with the same selection medium conditions as A549 
WT and H1299 cell lines may lead to a more reliable conclusion. 
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